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Abstract
Background: Dysregulation of apoptosis, specifically overexpression of soluble Fas (sFas), has
been proposed to play a role in the development of ovarian cancer. The main objective of the
present study was to evaluate serum sFas as a potential biomarker of ovarian cancer risk.
Methods: The association between serum sFas levels and the risk of ovarian cancer was examined
in a case-control study nested within three prospective cohorts in New York (USA), Umeå
(Sweden), and Milan (Italy). Case subjects were 138 women with primary invasive epithelial ovarian
cancer diagnosed between 2 months and 13.2 years after the initial blood donation. Control
subjects were 263 women who were free of cancer, and matched the case on cohort, menopausal
status, age, and enrollment date. Serum sFas levels were determined using a quantitative sandwich
enzyme immunoassay.
Results: Serum sFas levels were similar in women subsequently diagnosed with ovarian cancer
(median, 6.5 ng/mL; range, 4.4 – 10.2) and in controls (median, 6.8 ng/mL; range, 4.5 – 10.1).
Statistically significant trends of increasing serum sFas with age were observed among cases (r =
0.39, p < 0.0001) and controls (r = 0.42, p < 0.0001). Compared to women in the lowest third,
women in the highest third of serum sFas were not at increased risk of ovarian cancer after
adjustment for potential confounders (odd ratio (OR), 0.87; 95% confidence interval (CI), 0.42 –
1.82).
Conclusion: The results suggest that serum sFas may not be a suitable marker for identification
of women at increased risk of ovarian cancer.
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Background
Ovarian cancer remains the most deadly gynecologic
tumor in the United States [1] and Europe [2]. In 2003,
the American Cancer Society estimated that 25,400
women in the United States will be diagnosed with ovar-
ian cancer, and 14,300 will die from the disease [1]. Accu-
mulating experimental evidence suggests that the
dysregulation of apoptosis, specifically a failure to elimi-
nate ovarian epithelial inclusion cysts in the stroma, may
play a role in the pathogenesis of the disease [3,4]. One of
the major regulators of programmed cell death or apopto-
sis is the Fas/FasL system. Fas (Apo-1, CD95) is a member
of the tumor necrosis factor receptor (TNF-R) superfamily
[5] and can occur as both a cell-surface and a soluble pro-
tein (sFas). The interaction between Fas ligand (FasL) and
cell-surface Fas induces apoptosis in sensitive cells
through the activation of an intracellular Fas-associated
death domain, the recruitment of caspase-8 and the acti-
vation of a cascade of proteases, resulting in proteolysis
and degradation of chromosomal DNA [5]. Soluble Fas is
usually generated by alternative mRNA splicing and lacks
a transmembrane domain. By binding to FasL, sFas is
thought to inhibit cell-surface Fas-FasL signaling and
downregulate Fas-mediated apoptosis [6]. Elevated serum
levels of sFas have been detected in ovarian cancer
patients [4,7,8]. Serum sFas levels have been shown to
correlate directly with advanced stage and increased
tumor burden [9] and have been proposed as a prognostic
factor in patients with gynecologic malignancies [8]. It has
been hypothesized that circulating levels of sFas may be
also reflective of risk of subsequent development of ovar-
ian cancer. The objective of the present study was to eval-
uate the association between serum sFas levels and risk of
ovarian cancer using samples collected in advance of clin-




The prospective cohorts in this study included the New
York University Women's Health Study (NYUWHS), the
Northern Sweden Health and Disease Study (NSHDS),
and the Italian study of Hormones and Diet in the Etiol-
ogy of Breast Tumors (ORDET). The cohorts have been
described in detail previously [10-12]. Overall study coor-
dination was provided through the International Agency
for Research on Cancer (IARC).
At the time of recruitment, cohort members were admin-
istered questionnaire focusing on demographic (race, eth-
nicity, occupation), anthropometric (height, weight, body
mass index), reproductive history (age at menarche, age at
first full-term pregnancy, age at menopause), family his-
tory of cancer, medical history, and medication use. The
quality of information collected at baseline was compara-
ble between the three participating cohorts. Subjects who
reported hormone use at baseline were not eligible in the
NYUWHS and the ORDET cohorts, and potential case and
control subjects from the NSHDS who reported use of
exogenous hormones were also considered ineligible for
this study. At recruitment, all cohort members were asked
to donate venous blood samples, which have been stored
at -80°C for subsequent biochemical analyses. Samples
chosen for this study were selected among the specimens
that never undergo freeze-thaw cycles previously.
Nested case-control study
Eligible cases were subjects with primary, invasive epithe-
lial ovarian cancer diagnosed at least 2 months after the
initial blood donation and identified within each parent
cohort by the date of the last complete follow-up. In the
NYUWHS, follow-up consists of periodic (every 2–5
years) contacts of subjects by mail and telephone, as well
as record linkages with the statewide tumor registries of
New York, New Jersey, Connecticut and Florida, and with
the U.S. National Death Index. In the NSHDS, ovarian
cancer cases were identified through linkages with
regional and national cancer registries and the vital status
of the study participants was ascertained by record linkage
to the regional and national registries for all-cause mortal-
ity. The ORDET database was linked to the regional Lom-
bardy Cancer Registry to identify ovarian cancer cases, and
to the regional residents' files to verify the vital status of
the cohort members. The dates of last complete follow-up
were January 1998, December 2000, and January 1997 for
the NYUWHS, NSHDS, and ORDET, respectively. A total
of 138 ovarian cancer cases met the eligibility criteria and
were included in this study from the three parent cohorts
(74 cases from the NYUWHS, 47 cases from the NSHDS,
and 17 cases from the ORDET study). Additional serum
samples collected during annual examinations were avail-
able for a subset of the NYUWHS subjects (30 cases, 59
controls).
For each case, two controls per case were randomly
selected among appropriate risk sets. The risk set for a
given case included cohort subjects who were alive and
free of cancer, have not had a bilateral oophorectomy, and
matched the case on cohort, age (± 6 months), date of
recruitment (± 3 months), self-reported menopausal sta-
tus at enrollment, and, for premenopausal women, day of
the menstrual cycle at blood donation (for NYUWHS and
ORDET subjects only). The goodness of matching for
menopausal status was confirmed by FSH measurements
(FSH levels ≤ 12.5 µIU/mL were considered premenopau-
sal), as previously described [13,14]. A total of 276 eligi-
ble matching controls were identified. Eleven potential
controls were excluded because of the lack of serum and
two controls were excluded because their FSH levels did
not match their reported menopausal status. A total ofBMC Cancer 2003, 3 http://www.biomedcentral.com/1471-2407/3/33
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138 ovarian cancer cases and 263 matching controls were
included in the study.
The Institutional Review Boards of the New York Univer-
sity School of Medicine, the University of Umeå and Insti-
tuto Nazionale Tumori in Milan reviewed and approved
the present study.
Laboratory analyses
The samples from the NSHDS and ORDET were shipped
on dry ice to the Reproductive Biology Research Labora-
tory at the Department of Obstetrics and Gynecology,
NYU School of Medicine. Levels of sFas were measured at
the NYU School of Medicine laboratory using a quantita-
tive sandwich enzyme immunoassay technique according
to manufacturer (Quantikine Human sFas Immunoassay,
R&D Systems Inc., MN). Blood serum samples from each
case and her matching controls were always analyzed in
the same batch by a laboratory technician who was una-
ware of their disease status. Concentrations of sFas in nan-
ograms per milliliter (ng/mL) were calculated using a
standard curve generated for each set of samples. All sam-
ples were analyzed in duplicate and the average of two
measurements was used to calculate serum sFas levels. The
assay sensitivity defined as the minimum detectable con-
centration of sFas is 0.02 ng/mL. The intra-assay and inter-
assay coefficients of variation provided by the laboratory
were 3.1% and 4.5%, respectively. Furthermore, this assay
demonstrated no significant cross-reactivity or interfer-
ence with 92 common cytokines and growth factors.
Statistical analyses
In order to reduce departures from the normal distribu-
tion, sFas levels, weight, height, and body mass index
(BMI, calculated as weight in kilograms divided by the
square of height in meters) were log-transformed. A mixed
effects linear regression model was used to compare con-
tinuous variables between cases and controls, taking into
account the matched design [15]. Categorical characteris-
tics of cases and controls were compared using the condi-
tional logistic regression model. Spearman correlation
coefficients were calculated to quantify the strength of
associations between serum sFas levels and various sub-
jects' characteristics. A multivariate linear regression
model estimated by the least squares was also used to
identify factors predictive of sFas levels.
To compute odds ratios for ovarian cancer, sFas measure-
ments were categorized into tertiles, using the frequency
distribution of cases and controls combined. The condi-
tional logistic regression model was used to take into
account the matching. Odds ratios were computed rela-
tive to the lowest tertile. The effect of potential confound-
ing variables (parity, use of oral contraceptives, and BMI)
was assessed by including these variables in the logistic
regression model containing sFas one at a time, as well as
by including them simultaneously. When assessing the
effect of BMI, height was also included in the model
because it has been shown that, if obesity is a risk factor,
including only BMI in a model forces an inverse-quadratic
relation of height to risk given weight [16]. Likelihood
ratio tests were used to assess statistical significance and p-
values for trends. Reported trend test p-values correspond
to sFas treated as an ordered categorical variable. The sta-
tistical analyses were performed using Statistical Analysis
Software, Version 8.0 (SAS Institute Inc., Cary, NC).
Results
Common epithelial-type ovarian tumors were observed,
such as serous (n = 59), mucinous (n = 14), endometrioid
(n = 14), clear cell (n = 7), mixed (n = 1), and not-other-
wise-specified adenocarcinoma (n = 25). Histology was
unknown for eighteen cases. For all cases combined,
median period from the initial visit to the diagnosis of
ovarian cancer was 5.1 years (range, 2 months – 13.2
years).
Selected descriptive characteristics of study subjects strati-
fied by participating cohort are presented in Table 1 (see
Additional file 1). The median age at diagnosis of ovarian
cancer was 61 years in the NYUWHS, 59 years in the
NSHDS study, and 54 years in the ORDET study. Because
of the matching, ovarian cancer cases and controls had
similar proportions of premenopausal and postmenopau-
sal women and similar age at enrollment. There were no
significant differences in the ages at menarche or at first
full-term pregnancy between the cases and controls. Ovar-
ian cancer cases were more likely to report nulliparity,
later age at menopause (all cohorts), a positive first-degree
history of breast cancer (the NYUWHS and the ORDET
cohorts) and less likely to report use of oral contraceptives
(the NSHDS and the ORDET cohorts) as presented in
Table 1 (see Additional file 1). Among all subjects, signif-
icant case-control differences were observed in parity (p =
0.02) and age at menopause (p = 0.03). In agreement with
previous report based on the same cohorts [14], in the
combined studies analysis ovarian cancer cases had lower
BMI (mean, 25.0 kg/m2), as compared to control subjects
(mean, 26.0 kg/m2) (p < 0.04).
Table 1 reports the means, medians, standard deviations
and ranges of serum sFas levels in ovarian cancer cases and
controls. No statistically significant differences in sFas lev-
els were observed between cases and controls in the total
study population, within the participating cohorts, and
after stratification by menopausal status. Serum sFas levels
were slightly higher in the NSHDS subjects, as compared
to the NYUWHS and ORDET subjects but the differences
between cohorts were not statistically significant (Table
1).BMC Cancer 2003, 3 http://www.biomedcentral.com/1471-2407/3/33
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The associations between serum sFas levels expressed as
tertiles and risk of ovarian cancer are reported in Table 2.
No statistically significant associations were observed in
unadjusted analyses, nor in analyses adjusting for poten-
tial confounders (parity, use of oral contraceptives, BMI,
and height) included in the statistical model either one at
a time, or simultaneously. Both unadjusted and adjusted
simultaneously for potential confounders, models are
presented.
Because it has been suggested that sFas can be produced
and shed into circulation by tumor [9], we explored the
hypothesis that sFas levels increase closer to diagnosis
with increasing ovarian tumor load and could serve as a
marker of yet undiagnosed disease. First, we assessed
serum sFas levels stratified by lagtime to the index date
(ovarian cancer diagnosis). There were no significant dif-
ferences in sFas levels stratified by lagtime to the index
date among ovarian cancer cases and their matching con-
trols (Figure 1). We also observed no statistically signifi-
cant associations between prediagnostic serum sFas and
tumor stage (Ptrend = 0.54) or grade (Ptrend = 0.76).
In addition, we examined the changes over time in sFas
levels among subjects for whom repeated blood dona-
tions were available (30 cases and 59 matched controls
from the NYUWHS cohort). For cases, median time
between the first and second visits was 376 days, median
sFas difference between the first and repeated measure-
ments was -0.19 ng/mL and median rate of change was -
4.1 × 10-4 ng/mL/day. For controls, median time between
two visits was 378 days, median sFas difference between
the first and repeated measurements was 0.10 ng/mL and
median rate of change was 2.8 × 10-4 ng/mL/day. The
Table 2: Serum sFas levels in ovarian cancer cases and controls from the three participating cohorts
Cohort Serum sFas, ng/mL
Cases Controls P-value*
NYUWHS
n 74 145 0.37
Mean (SD) 6.8 (2.2) 6.7 (2.1)
Median (10th–90th percentiles) 6.5 (4.3 – 9.8) 6.5 (4.2 – 9.5)
NSHDS
n 47 86 0.20
Mean (SD) 8.1 (7.4) 8.0 (2.2)
Median (10th–90th percentiles) 6.6 (4.8 – 10.9) 7.6 (5.5 – 11.2)
ORDET
n 17 32 0.07
Mean (SD) 6.2 (1.3) 6.7 (1.3)
Median (10th–90th percentiles) 6.6 (3.9 – 7.6) 6.4 (5.2 – 8.1)
Total
n 138 263 0.51
Mean (SD) 7.2 (4.6) 7.1 (2.2)
Median (10th–90th percentiles) 6.5 (4.4 – 10.2) 6.8 (4.5 – 10.1)
* Mixed effect linear regression model (after natural log-transformation). SD, standard deviation.
Table 3: Odds ratios of ovarian cancer for tertiles of serum sFas levels
Serum sFas tertiles, ng/mL Cases n (%) Controls n (%) OR (95%CI)
Unadjusted* Adjusted**
<5.9 51 (37%) 83 (32%) 1.00 1.00
5.9 – 7.6 46 (33%) 88 (33%) 0.86 (0.50 – 1.48) 0.93 (0.49 – 1.78)
>7.6 41 (30%) 92 (35%) 0.69 (0.37 – 1.28) 0.87 (0.42 – 1.82)
p for trend*** 0.24 0.71
* Except for matching on cohort, age, menopausal status, and date of blood donation. ** Adjusted for parity, use of oral contraceptives, BMI (log-
transformed), and height (log-transformed), *** Conditional logistic regression model (sFas treated as ordered categorical variable).BMC Cancer 2003, 3 http://www.biomedcentral.com/1471-2407/3/33
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difference in rate of change between ovarian cancer cases
and matched controls with repeated blood donations was
not statistically significant (p = 0.81). Spearman correla-
tion coefficient between first and second sFas measure-
ments was 0.72 (p < 0.0001).
Little is known about factors that determine physiological
sFas levels. To identify the factors that may be related to
serum sFas, we examined correlations of sFas levels with
known characteristics of control subjects. There was a
direct and statistically significant correlation between
serum sFas and age (Spearman r = 0.42, p < 0.0001) (Fig-
ure 2). Similar positive correlation between serum sFas
and age was observed among cases (Spearman r = 0.39, p
< 0.0001). We also analyzed the effect of menopausal sta-
tus on sFas levels. Results of a linear regression analysis
indicated that sFas levels were positively associated with
age (p < 0.002) but not with menopausal status (p = 0.52).
After adjustment for age, no significant correlations were
observed between serum sFas and selected subjects' char-
acteristics, such as age at menarche, age at first full-term
pregnancy, age at menopause, weight, height, and BMI.
Discussion
The Fas-FasL system is a primary mediator of apoptosis in
many major physiologic processes. The proposed roles of
Fas-mediated apoptosis include the elimination of acti-
vated T-cells following an immune response, the killing of
tumor and virally infected cells by cytotoxic T-cells and
natural killer cells, and maintenance of immune-privi-
leged sites such as the eye, testis, and maternal-fetal
interface.
Dysregulation of Fas-mediated apoptosis is thought to
play a role in the development of various tumors, includ-
ing ovarian cancer [3,4]. It has been proposed that cancer
cells expressing FasL have an advantage to evade human
immune surveillance by inducing apoptosis in infiltrating
lymphocytes expressing Fas. It is known that some tumor
cells express both Fas and FasL yet are resistant to Fas-
mediated apoptosis. This phenomenon has been attrib-
uted to receptor dysfunction, or intracellular inhibition by
FLICE inhibitory protein (FLIP) that blocks Fas-mediated
tumor cell death, enabling the tumor to avoid immune
clearance [17].
Soluble form of Fas receptor, which is lacking the trans-
membrane domain of the cell-surface Fas, is thought to
compete for FasL with Fas receptor expressed on tumor
cells and, therefore, alter or prevent apoptotic signal trans-
duction [6]. Previously, several hospital-based case-con-
trol studies have shown that circulating sFas levels were
significantly elevated in ovarian cancer patients as
compared to controls [4,7,8] and it has been proposed
that serum sFas levels or FasL expression may serve as a
prognostic factor in patients with ovarian cancer and
other gynecological malignancies [8,18].
Levels of sFas by lagtime from the blood donation to the  index date (ovarian cancer diagnosis) Figure 1
Levels of sFas by lagtime from the blood donation to the 
index date (ovarian cancer diagnosis). Bars show means and 
95% confidence intervals. There were no significant differ-
ences in sFas levels stratified by lagtime to the index date 
among ovarian cancer cases (p = 0.38) and matching controls 
(p = 0.80).
Correlation between age and sFas levels in the control group Figure 2
Correlation between age and sFas levels in the control 
group. There was a significant correlation (Spearman r = 
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The objective of the current study was to evaluate serum
sFas as a predictive marker of ovarian cancer risk. In this
case-control study nested within prospective cohorts, we
observed no association between serum sFas levels and
subsequent risk of subsequent ovarian cancer, before and
after adjustment for potential confounders.
Several factors should be taken into consideration in the
interpretation of these results. The levels of serum sFas
observed in our study were markedly higher than in ear-
lier studies [4,7,8]. While two of the previous studies [7,8]
used sFas ELISA assays (Medical & Biological Laboratories
Co., Nagoya, Japan), the present study used a quantitative
sandwich enzyme immunoassay technique (Quantikine
Human sFas Immunoassay, R&D Systems Inc., MN), a
very sensitive and specific assay. Therefore, the observed
differences in serum sFas levels between the current and
previous studies could reflect variations in laboratory
assay methods.
The discrepancy in results between this case-control study
nested within prospective cohorts and previous retrospec-
tive hospital-based studies may also be related to the ori-
gins of sFas. Although the precise cellular source of serum
sFas remains unclear, increased sFas levels in culture
supernatants of breast and colon cancer cells lead to the
assumption that sFas is derived from tumor cells [9]. It has
been shown that serum sFas are elevated in patients with
more advanced tumor stages [7-9] and that serum sFas
levels decrease after surgical resection, as compared with
levels obtained before surgery [9]. These findings suggest
that sFas is produced and shed into circulation by tumor
and that serum sFas levels could be reflective of tumor
bulk. This may explain the results of previous hospital-
based case-control studies suggesting that sFas can be used
as a prognostic marker in patients with advanced ovarian
cancer, as well as the lack of association between serum
sFas and ovarian cancer observed in this prospective
study, for which serum samples were collected up to 13.2
years before diagnosis.
Soluble Fas can also be produced by activated peripheral
blood lymphocytes [19] and it has been postulated that
dysfunction of apoptotic pathways or production of solu-
ble factors including sFas and soluble FasL may be
involved in the pathogenesis of several autoimmune dis-
eases [20] and in cancer [3,4,21]. We observed a strong
positive correlation between age and serum sFas suggest-
ing that circulating sFas levels are increasing with age.
Because the incidence of cancer and autoimmune disease
also increases with age, this observation provides addi-
tional indirect evidence for a possible role of apoptosis
dysregulation in these conditions. Future studies of sFas
should consider taking into account the age-related
changes in circulating sFas levels.
Conclusions
In conclusion, previous studies have demonstrated that
serum sFas could be a useful prognostic factor in women
who are already diagnosed with ovarian cancer. However,
the results of the present study, which observed lack of
association between prediagnostic serum sFas and ovarian
cancer diagnosed later in life, suggest that serum sFas may
not be a suitable susceptibility marker for identification of
women at increased risk of the disease.
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